Literature DB >> 16820789

ADMA, proteinuria, and insulin resistance in non-diabetic stage I chronic kidney disease.

K Caglar1, M I Yilmaz, A Sonmez, E Cakir, A Kaya, C Acikel, T Eyileten, M Yenicesu, Y Oguz, C Bilgi, C Oktenli, A Vural, C Zoccali.   

Abstract

The rationale of this study is based on the fact that, both proteinuria and elevated asymmetric dimethyl arginine (ADMA) levels have been linked to the progression of vascular disease. Currently, there is not enough knowledge about any association between the levels of proteinuria and ADMA levels. Seventy-eight non-diabetic patients (42 men, 36 women, mean age of 26.1+/-5.2 years) with proteinuria having normal glomerular filtration rate were enrolled along with 38 healthy subjects (20 men, 18 women, mean age of 26.9+/-5.9 years). Proteinuria was below 3.5 g/day in 40 patients and above 3.5 g/day in 38 patients. Both groups had similar age, gender, and body mass index distributions. Serum ADMA, symmetric dimethyl arginine (SDMA), immunoreactive insulin, and high sensitivity C reactive protein (hsCRP) levels were measured. Insulin resistance was determined by homeostasis model assessment (HOMA). Serum ADMA, SDMA, insulin, hsCRP levels, and HOMA indexes were significantly higher in patients than in healthy control subjects. The above parameters were higher in the nephrotic range proteinuria group when compared to patients having protein levels below 3.5 g/day. There were significant correlations between the levels of proteinuria and the above parameters. According to the regression analysis, levels of proteinuria and hsCRP were significant determinants of serum ADMA levels. Our results indicate that, independent of other risk factors, ADMA is directly associated with proteinuria. Further studies are recommended to find out whether elevated ADMA levels are implicated in the high cardiovascular risk of proteinuric nephropathies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16820789     DOI: 10.1038/sj.ki.5001632

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  30 in total

1.  Symmetric dimethylarginine as a proinflammatory agent in chronic kidney disease.

Authors:  Eva Schepers; Daniela V Barreto; Sophie Liabeuf; Griet Glorieux; Sunny Eloot; Fellype C Barreto; Ziad Massy; Raymond Vanholder
Journal:  Clin J Am Soc Nephrol       Date:  2011-08-04       Impact factor: 8.237

Review 2.  The role of asymmetric and symmetric dimethylarginines in renal disease.

Authors:  Edzard Schwedhelm; Rainer H Böger
Journal:  Nat Rev Nephrol       Date:  2011-03-29       Impact factor: 28.314

3.  Coronary artery calcification, ADMA, and insulin resistance in CKD patients.

Authors:  Shuzo Kobayashi; Machiko Oka; Kyoko Maesato; Ryota Ikee; Tsutomu Mano; Moriya Hidekazu; Takayasu Ohtake
Journal:  Clin J Am Soc Nephrol       Date:  2008-06-18       Impact factor: 8.237

4.  The relationship between hemoglobin levels and endothelial functions in diabetes mellitus.

Authors:  Alper Sonmez; Mahmut Ilker Yilmaz; Mutlu Saglam; Selim Kilic; Tayfun Eyileten; Gokhan Uckaya; Kayser Caglar; Yusuf Oguz; Abdulgaffar Vural; Mujdat Yenicesu; Mustafa Kutlu; Can Kinalp; Carmine Zoccali
Journal:  Clin J Am Soc Nephrol       Date:  2009-10-15       Impact factor: 8.237

5.  Reduction of plasma asymmetric dimethylarginine in obese patients with chronic kidney disease after three years of a low-protein diet supplemented with keto-amino acids: a randomized controlled trial.

Authors:  Vladimir Teplan; Otto Schück; Jaroslav Racek; Olga Mareckova; Milena Stollova; Vladimir Hanzal; Jan Malý
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

Review 6.  Cardiovascular implications of proteinuria: an indicator of chronic kidney disease.

Authors:  Varun Agrawal; Victor Marinescu; Mohit Agarwal; Peter A McCullough
Journal:  Nat Rev Cardiol       Date:  2009-04       Impact factor: 32.419

7.  Asymmetric dimethylarginine and mortality in stages 3 to 4 chronic kidney disease.

Authors:  Jill Melendez Young; Norma Terrin; Xuelei Wang; Tom Greene; Gerald J Beck; John W Kusek; Allan J Collins; Mark J Sarnak; Vandana Menon
Journal:  Clin J Am Soc Nephrol       Date:  2009-04-23       Impact factor: 8.237

Review 8.  Asymmetric dimethylarginine (ADMA) is a novel emerging risk factor for cardiovascular disease and the development of renal injury in chronic kidney disease.

Authors:  Seiji Ueda; Sho-Ichi Yamagishi; Yuriko Matsumoto; Kei Fukami; Seiya Okuda
Journal:  Clin Exp Nephrol       Date:  2007-06-28       Impact factor: 2.801

9.  Blood content of asymmetric dimethylarginine: new insights into its dysregulation in renal disease.

Authors:  Scott S Billecke; Louis G D'Alecy; Raylene Platel; Steven E Whitesall; Kenneth A Jamerson; Rachel L Perlman; Crystal A Gadegbeku
Journal:  Nephrol Dial Transplant       Date:  2008-09-15       Impact factor: 5.992

Review 10.  Asymmetrical dimethylarginine in renal disease: limits of variation or variation limits? A systematic review.

Authors:  Johannes Jacobi; Philip S Tsao
Journal:  Am J Nephrol       Date:  2007-10-24       Impact factor: 3.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.